Imaging gene-substance interactions: The effect of the DRD2 TaqIA polymorphism and the dopamine agonist bromocriptine on the brain activation during the anticipation of reward

Neuroscience Letters

Volumn 405, Issue 3, 2006, Pages 196-201

  Kirsch, Peter ^a   Reuter, Martin ^a   Mier, Daniela ^a   Lonsdorf, Tina ^a   Stark, Rudolf ^a   Gallhofer, Bernd ^a   Vaitl, Dieter ^a   Hennig, Jürgen ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Addiction; Dopamine; DRD2; fMRI; Genetics; Reward

Indexed keywords

BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; PLACEBO;

ADULT; ALLELE; ANTICIPATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPAMINE BRAIN LEVEL; DOPAMINERGIC ACTIVITY; DOUBLE BLIND PROCEDURE; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE FREQUENCY; GENE INTERACTION; GENE LOCATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; MALE; NEUROIMAGING; NEUROMODULATION; NORMAL HUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR DENSITY; RECEPTOR GENE; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR SENSITIVITY; REWARD; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; BRAIN; BROMOCRIPTINE; CROSS-SECTIONAL STUDIES; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; FEEDBACK, PSYCHOLOGICAL; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; OXYGEN; POLYMORPHISM, GENETIC; REACTION TIME; RECEPTORS, DOPAMINE D2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; REWARD;

EID: 33746863313     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2006.07.030     Document Type: Article

References (17)

1. Blum K., Braverman E.R., Holder J.M., Lubar J.F., Monastra V.J., Miller D., Lubar J.O., Chen T.J., and Comings D.E. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J. Psychoactive Drugs 32 Suppl. i-iv (2000) 1-112
2. Bowirrat A., and Oscar Berman M. Relationship between dopaminergic neurotransmission, alcoholism, and reward deficiency syndrome. Am. J. Med. Genet. B Neuropsychiatr. Genet. 132 (2005) 29-37
3. Dodd M.L., Klos K.-J., Bower J.H., Geda Y.E., Josephs K.A., and Ahlskog J.E. Pathological gambling caused by drugs used to treat Parkinson disease. Arch. Neurol. 62 (2005) 1377-1381
4. Hallikainen T., Hietala J., Kauhanen J., Pohjalainen T., Syvalahti E., Salonen J.T., and Tiihonen J. Ethanol consumption and DRD2 gene TaqI a polymorphism among socially drinking males. Am. J. Med. Genet. A 119 (2003) 152-155
5. Jönsson E.G., Nothen N.M., Grunhage F., Farde L., Nakashima Y., Propping P., and Sedvall G.C. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol. Psychiatry 4 (1999) 290-296
6. Kirsch P., Schienle A., Stark R., Sammer G., Blecker C., Walter B., Ott U., Burkart J., and Vaitl D. Anticipation of reward in a nonaversive differential conditioning paradigm and the brain reward system: an event-related fMRI study. Neuroimage 20 (2003) 1086-1095
7. Knutson B., Adams C.M., Fong G.W., and Hommer D. Anticipation of increasing monetary reward selectively recruits nucleus accumbens. J. Neurosci. 21 (2001) RC159
8. Lawford B.R., Young R.M., Rowell J.A., Qualichefski J., Fletcher B.H., Syndulko K., Ritchie T., and Noble E.P. Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele. Nat. Med. 1 (1995) 337-341
9. Mattay V.S., Goldberg T.E., Fera F., Hariri A.R., Tessitore A., Egan M.F., Kolachana B., Callicott J.H., and Weinberger D.R. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 6186-6191
10. Noble E.P. Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: a review. Eur. Psychiatry 15 (2000) 79-89
11. Ott U., Reuter M., Hennig J., and Vaitl D. Evidence for a common biological basis of the absorption trait, hallucinogen effects, and positive symptoms: epistasis between 5-HT2a and COMT polymorphisms. Am. J. Med. Genet. B Neuropsychiatr. Genet. 137 (2005) 29-32
12. Persico A.M., Bird G., Gabbay F.H., and Uhl G.R. D2 dopamine receptor gene TaqI A1 and B1 restriction fragment length polymorphisms: enhanced frequencies in psychostimulant-preferring polysubstance abusers. Biol. Psychiatry 40 (1996) 776-784
13. Reuter M., and Hennig J. Pleiotropic effect of the TPH A779C polymorphism on nicotine dependence and personality. Am. J. Med. Genet. B Neuropsychiatr. Genet. 134 (2005) 20-24
14. Reuter J., Raedler T., Rose M., Hand I., Glascher J., and Büchel C. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat. Neurosci. 8 (2005) 147-148
15. Reuter M., Schmitz A., Corr P., and Hennig J. Molecular genetics support Gray's personality theory: the interaction of COMT and DRD2 polymorphisms predicts the behavioural approach system. Int. J. Neuropsychopharmacol. (2006) 155-166
16. Schultz W. Getting formal with dopamine and reward. Neuron 36 (2002) 241-263
17. Tran A.H., Tamura R., Uwano T., Kobayashi T., Katsuki M., Matsumoto G., and Ono T. Altered accumbens neural response to prediction of reward associated with place in dopamine D2 receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 8986-8991